Oscient Pharmaceuticals to Present at First Albany Capital Annual Growth Conference; Webcast of Presentation Available Tuesday, December 7, 2004 at 2:40 PM ET
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the First Albany Capital Annual Growth Conference on December 7, 2004 in New York City. The Company’s President and CEO, Steven Rauscher, will provide an overview of the Company as well as an update on the recent launch of FACTIVE(R) (gemifloxacin mesylate) tablets, the Company’s lead product. The presentation will begin at 2:40 PM ET on Tuesday and will be webcast through the Company’s website at www.oscient.com. An archive of the webcast will also be available for 30 days.
About Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to the clinical development and commercialization of novel therapeutics to address unmet medical needs. The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. In addition to the oral tablet form, Oscient Pharmaceuticals is developing an investigational FACTIVE intravenous formulation for use in hospitalized patients.
The Company has a novel antibiotic candidate, Ramoplanin, in advanced clinical development for the treatment of Clostridium difficile-associated diarrhea (CDAD). The Company’s preclinical program includes an oral peptide deformylase (PDF) inhibitor series, under preclinical development for community-based respiratory tract infections.